Parasite Drug Shows Effectiveness Against Mesothelioma
Dr. Antonio Giordano believes his team has cleared the path to the next breakthrough in the treatment of malignant pleural mesothelioma. The advancement involves a new use for an old drug, pyrvinium pamoate, which doctors have successfully used for more than 50 years to treat infections of pinworm parasite. “This drug that no one expected to be involved with mesothelioma is potentially a new weapon against this aggressive type of tumor,” Giordano told Asbestos.com. “Our findings are exciting, very exciting. This one can move forward.” Giordano is the founder and director of the Sbarro Health Research Organization (SHRO) at Temple University in Philadelphia. He also is an internationally renowned professor of pathology and oncology at the University of Sienna in Italy. His expertise involves identifying novel targets and therapies at the molecular level. This particular drug has shown promise with mesothelioma as well as pancreatic and breast cancer. Better Mesothelioma Treatments Needed The findings have been published in the latest issue of Journal of Cell Physiology. A summary is available on the SHRO website. “This should trigger interest and attention of oncologists all over the world to work on it,” Giordano said. “It’s now about taking the initiative to bring this drug to the clinical bedside, to the patients.” Pleural mesothelioma, which is caused by exposure to asbestos, is a rare and aggressive cancer with no defi...
Authors: Charytoniuk T, Małyszko M, Bączek J, Fiedorczyk P, Siedlaczek K, Małyszko J Abstract Nephrectomy, which constitutes a gold-standard procedure for the treatment of renal-cell carcinoma (RCC), has been widely discussed in the past decade as a significant risk factor of the development of chronic kidney disease (CKD). RCC is the third most common genitourinary cancer in the United States, with an estimated more than 65,000 new cases and 14,970 deaths. The aim of this review was to precisely and comprehensively summarize the status of current knowledge in chronic kidney disease risk factors after nephrectom...
Authors: Russo Picasso MF, Vicens J, Giuliani C, Jaén ADV, Cabezón C, Figari M, Gómez Saldaño AM, Figar S Abstract Background: Two hypotheses attempt to explain the increase of thyroid cancer (TC) incidence: overdetection by excessive diagnostic scrutiny and a true increase in new cases brought about by environmental factors. Changes in the mechanism of detection and the risk of incidentally diagnosed TC could result in an increase of TC incidence. Methods: Retrospective cohort study. We identified incident cases of TC from the pathological reports of patients in a HMO and review of ...
Contributors : Ting La ; Xu D ZhangSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Mus musculusTo investigate miRNAs in quiescent cancer cell
(MedPage Today) -- Also, breast-conserving surgery or mastectomy?
(Reuters Health) - People with diabetes are more likely to develop certain cancers than those without the condition, and a new analysis suggests that the increased risk is greater for women than for men.
Publication date: Available online 15 August 2018Source: SteroidsAuthor(s): Julius Fink, Masahito Matsumoto, Yoshifumi TamuraAbstractSedentary lifestyle and over-nutrition are the main causes of obesity and type 2 diabetes (T2D). However, the same causes are major triggers of hypogonadism. Many T2D patients show low testosterone levels while hypogonadal men seem to be prone to become diabetic. Testosterone plays a major role in the regulation of muscle mass, adipose tissue, inflammation and insulin sensitivity and is therefore indirectly regulating several metabolic pathways, while T2D is commonly triggered by insulin resi...
(Reuters Health) - Cancer patients who use alternative, non-medical therapies may be more likely to forgo recommended medical treatments like chemotherapy and radiation, and be more likely to die as a result, a U.S. study suggests.
The herbicide gyphosate is the world ’ s most popular weedkiller. There is widespread disagreement among lawyers, researchers and regulators over any potential links to cancer.
The now published results from the EMBRACA study confirm that talazoparib prolongs progression-free survival in advanced BCRA-positive breast cancer.Medscape Medical News
The regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment. Here, we reflect on our experience administering the carboplatin/paclitaxel regimen to scores of ovarian cancer patients over the past decade and a half.
More News: Asbestosis | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Enterobiasis | Environmental Health | Genetics | Immunotherapy | Italy Health | Laboratory Medicine | Mesothelioma | Pancreas | Pancreatic Cancer | Parasitic Diseases | Parasitology | Pathology | Physiology | Study | Websites